Use of quinine and mortality‐risk in patients with heart failure—a Danish nationwide observational study

Abstract

Use of quinine was common and associated with increased mortality in heart failure, especially if administered together with β-blockers and shortly after treatment initiation. Mechanisms underlying the findings remain to be established.

Effect of age on the effectiveness of the first-line standard of care treatment in patients with metastatic colorectal cancer: systematic review of observational studies

“…The median follow-up period was 22.8 months based on the six studies that reported this information. The median follow-up period was similar in retrospective studies (Dirican et al 2014; Fourrier-Reglat et al 2015; Slavicek et al 2014; Tahover et al 2015) and prospective studies (Kozloff et al 2010, 2011; Parakh et al 2015; Rouyer et al 2016), with 23.2 months and 22.5 months, respectively. In addition to the targeted therapies, which were bevacizumab or cetuximab, chemotherapy regimens included single-agent therapy (IV 5-fluorouracil or oral capecitabine) and/or combination therapy (mainly FOLFOX, FOLFIRI, XELOX, or XELIRI).…”

“…In addition to the targeted therapies, which were bevacizumab or cetuximab, chemotherapy regimens included single-agent therapy (IV 5-fluorouracil or oral capecitabine) and/or combination therapy (mainly FOLFOX, FOLFIRI, XELOX, or XELIRI). Among the 11 included studies, 5 used age categories other than ≥ 70 years vs. < 70 years or 65–75 years vs. ≥ 75 years (Dirican et al 2014; Fukuchi et al 2013; Fourrier-Reglat et al 2015; Parakh et al 2015; Sahm et al 2016). The median duration of therapy was reported in seven studies and ranged from 7 (Dirican et al 2014; Hofheinz et al 2014) to 9.97 months (Tahover et al 2015).…”

“…Five out of these seven studies reported the median duration of therapy by age group. Two studies (Fourrier-Reglat et al 2015; Slavicek et al 2014) showed a significantly shorter duration of therapy for elderly patients in comparison with younger patients. The other three studies (Kozloff et al 2010; Rouyer et al 2016; Tahover et al 2015) showed a similar duration of therapy between the different age groups.…”

“…The elderly presented a higher frequency of comorbidities and less aggressive treatment, which might have influenced the results. Only 6 out of 11 studies reported the use of propensity score matching to adjust for these baseline differences (Dirican et al 2014; Fourrier-Reglat et al 2015; Fukuchi et al 2013; Hofheinz et al 2014; Sahm et al 2016). The included studies did not consider the influence of the histological subtypes on tumour treatment (Hugen et al 2014).…”

Quinine exposure and the risk of acute kidney injury: a population-based observational study of older people

“…It also possesses alpha-adrenergic blocking properties that can predispose to hypotension [ 23 ]. In a Danish study of people with heart failure, quinine was associated with an increased risk of death, particularly with concurrent β-blocker therapy [ 24 ]. Side effects of quinine can occur at therapeutic doses and include tinnitus, hearing impairment, headache, nausea, vertigo and visual disturbance [ 8 ].…”